Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $4.7 million.

  • Angiodynamics' Cash from Operations rose 8847.55% to $4.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$5.6 million, marking a year-over-year increase of 7596.65%. This contributed to the annual value of -$10.1 million for FY2025, which is 6403.15% up from last year.
  • Angiodynamics' Cash from Operations amounted to $4.7 million in Q4 2025, which was up 8847.55% from -$15.9 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Cash from Operations registered a high of $18.8 million during Q2 2025, and its lowest value of -$25.9 million during Q3 2023.
  • In the last 5 years, Angiodynamics' Cash from Operations had a median value of $2.2 million in 2021 and averaged -$1.9 million.
  • In the last 5 years, Angiodynamics' Cash from Operations skyrocketed by 28634.72% in 2022 and then crashed by 101430.66% in 2024.
  • Over the past 5 years, Angiodynamics' Cash from Operations (Quarter) stood at $1.9 million in 2021, then soared by 286.35% to $7.5 million in 2022, then decreased by 29.78% to $5.3 million in 2023, then crashed by 53.04% to $2.5 million in 2024, then skyrocketed by 88.48% to $4.7 million in 2025.
  • Its Cash from Operations stands at $4.7 million for Q4 2025, versus -$15.9 million for Q3 2025 and $18.8 million for Q2 2025.